Oritavancin for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci Osteomyelitis

被引:11
作者
Foster, Rachel A. [1 ,2 ]
Philavong, Kingsavanh Paul [1 ]
Weissman, Sharon [3 ]
Tang, Xiaonan [4 ]
Bookstaver, P. Brandon [1 ,2 ]
机构
[1] Univ South Carolina, Coll Pharm, Dept Clin Pharm & Outcomes Sci, 715 Sumter St, Columbia, SC 29208 USA
[2] Palmetto Hlth, Dept Pharm, Columbia, SC USA
[3] Univ South Carolina, Sch Med, Div Infect Dis, Dept Med, Columbia, SC 29208 USA
[4] Frontage Labs Inc, Exton, PA USA
关键词
daptomycin; pharmacokinetics; prosthesis; oritavancin; osteomyelitis; vancomycin-resistant enterococci;
D O I
10.1097/IPC.0000000000000517
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vancomycin-resistant enterococci (VRE) are a growing cause of health care-associated infections globally, and limited treatment options exist for invasive VRE infections. Daptomycin is commonly used with modest success in the treatment of deep-seated infections secondary to VRE; however, there is concern for the emergence of daptomycin nonsusceptible VRE, especially during protracted courses, as required in osteomyelitis. We report the clinical and microbiologic success of a once-weekly, 6-week course of oritavancin with therapeutic drug monitoring in the treatment of daptomycin nonsusceptible VRE osteomyelitis secondary to prosthetic hip replacement. Our data suggest favorable pharmacokinetics and no treatment-related adverse events with once-weekly dosing. This report provides compelling information for future studies of prolonged oritavancin regimens in deep-seated infections.
引用
收藏
页码:97 / 99
页数:3
相关论文
共 15 条
[1]  
[Anonymous], 2014, OR PACK INS
[2]   Unmet Needs and Prospects for Oritavancin in the Management of Vancomycin-Resistant Enterococcal Infections [J].
Arias, Cesar A. ;
Mendes, Rodrigo E. ;
Stilwell, Matthew G. ;
Jones, Ronald N. ;
Murray, Barbara E. .
CLINICAL INFECTIOUS DISEASES, 2012, 54 :S233-S238
[3]   Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections [J].
Brade K.D. ;
Rybak J.M. ;
Rybak M.J. .
Infectious Diseases and Therapy, 2016, 5 (1) :1-15
[4]   Health and economic outcomes of vancomycin-resistant enterococci [J].
Carmeli, Y ;
Eliopoulos, G ;
Mozaffari, E ;
Samore, M .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) :2223-2228
[5]  
Johnson JR, 2015, OPEN FORUM INFECT DI, V2, DOI [10.1093/ofid/ofv002, 10.1093/ofid/ofv156]
[6]  
Judge Theresa, 2012, Infect Control Hosp Epidemiol, V33, P1250, DOI 10.1086/668438
[7]   Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians [J].
Kelesidis, Theodoros ;
Humphries, Romney ;
Uslan, Daniel Z. ;
Pegues, David A. .
CLINICAL INFECTIOUS DISEASES, 2011, 52 (02) :228-234
[8]   Oritavancin Pharmacokinetics and Bone Penetration in Rabbits [J].
Lehoux, Dario ;
Ostiguy, Valerie ;
Cadieux, Cordelia ;
Malouin, Mireille ;
Belanger, Odette ;
Far, Adel Rafai ;
Parr, Thomas R., Jr. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) :6501-6505
[9]   In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci [J].
Noviello, S ;
Ianniello, F ;
Esposito, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (02) :283-286
[10]   Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials [J].
Rubino, C. M. ;
Bhavnani, S. M. ;
Moeck, G. ;
Bellibas, S. E. ;
Ambrose, P. G. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) :3365-3372